Fungal Sinusitis
文献摘要
Fungal rhinosinusitis (FRS) encompasses a spectrum of immune and pathologic responses, including invasive, chronic, granulomatous, and allergic forms, yet consensus on terminology, pathogenesis, and optimal management remains lacking. Fungal spores pervade the environment and frequently come into contact with sinonasal structures evaluated by otolaryngology specialists, with fungi detectable in the nasal cavity and paranasal sinuses of nearly all individuals. Ongoing controversy surrounds diagnostic criteria and overlap between allergic fungal rhinosinusitis (AFRS) and chronic rhinosinusitis (CRS). Notably, the pathogenicity of these fungi arises only under favorable conditions, eg, prolonged antibiotic exposure, poor ventilation, dark and damp environments, and immunocompromised states, which disrupt normal immune defenses and increase susceptibility to infection. FRS is classified into noninvasive and invasive forms. Noninvasive disease includes saprophytic infestation, fungal ball, and AFRS, whereas invasive disease includes the subtypes acute invasive rhinosinusitis (AIRS), chronic invasive rhinosinusitis (CIRS), and granulomatous invasive fungal sinusitis (GIFS). Noninvasive disease requires both medical and surgical management, while invasive forms carry high morbidity and mortality without timely treatment. Clinical presentation may be acute, with rapid progression of symptoms lasting less than 30 days; subacute, with a duration of 30 to 90 days; or chronic, with slowly progressing symptoms lasting more than 90 days. Evaluation begins with a detailed clinical history and comprehensive head and neck examination, including nasal endoscopy and, when indicated, mucosal biopsy. Imaging typically involves computed tomography (CT) of the sinuses, with T1- and T2-weighted magnetic resonance imaging reserved for select cases. Magnetic resonance imaging (MRI) demonstrates high specificity for AFRS, particularly when combined with CT. Diagnostic support includes Bent and Kuhn criteria and serum immunoglobulin E (IgE) levels, which often exceed 1000 U/mL. Bent and Kuhn criteria serve as the diagnostic standard, requiring all major criteria for diagnosis, while minor criteria provide a supportive clinical context. Major criteria include type 1 hypersensitivity confirmed by history, skin testing, or in vitro testing; nasal polyposis; characteristic CT findings; eosinophilic mucin without tissue invasion; and positive fungal staining of sinus contents obtained during surgery. Minor criteria include asthma, unilateral disease predominance, radiographic bone erosion, positive fungal cultures, Charcot-Leyden crystals in surgical specimens, and serum eosinophilia. The pathogenesis of AFRS remains incompletely understood and continues to generate debate. Histopathologic evaluation remains essential for diagnosis. Hematoxylin-eosin–stained mucosal specimens typically show inflammatory infiltrates composed of eosinophils, lymphocytes, and plasma cells, along with mucosal hypertrophy and hyperplasia, without evidence of necrosis, granuloma formation, giant cells, or tissue invasion. Management strategies for allergic fungal sinusitis and other types of fungal sinusitis continue to evolve. Historically, surgical approaches emphasized aggressive mucosal removal, sometimes necessitating external procedures. Medical therapy includes oral corticosteroids, saline or combination nasal irrigations, topical intranasal corticosteroids, and immunotherapy, although the latter remains controversial. Dupilumab, an anti–interleukin-4/interleukin-13 (IL-4/IL-13) agent approved by the US Food and Drug Administration (FDA) for chronic rhinosinusitis with nasal polyps, shows uncertain efficacy in AFRS. Acute and chronic invasive fungal sinusitis (IFS) generally respond to systemic antifungal therapy following surgical intervention. Noninvasive fungal sinusitis primarily affects immunocompetent individuals, whereas invasive disease occurs more frequently in immunocompromised populations. IFS may progress to intracranial extension, contributing to increased morbidity and mortality. Immunocompromised patients require heightened vigilance and prompt, aggressive management when fungal sinusitis is suspected.